Skip to main content
Future Journal of Pharmaceutical Sciences

Table 3 The levels of NO (nmol/ml) and the expression levels of GLUT2 in all studied groups

From: Captopril pretreatment augments diabetogenic response to streptozotocin administration: experimental in vivo rat model

 

Control

STZ-30

STZ-30-Cap

STZ-40

STZ-40-Cap

STZ-50

STZ-50-Cap

NO nmol/ml

10.4 ± 0.21

29.88 ± 6.28*

59.38 ± 5.73*#

30.45 ± 7.6*$

58.03 ± 4.34*#€

33.33 ± 2.98*$¥

61.62 ± 2.4*#€@

GLUT2 relative expression

1.02 ± 0.18

1.07 ± 0.08

1.73 ± 0.12*#

1.02 ± 0.03$

1.77 ± 0.08*#€

1.01 ± 0.1$¥

1.73 ± 0.12*#€@

  1. Data presented by mean ± SD No = 6
  2. Statistical analysis was done using one-way ANOVA test followed by Tukey–Kramer post hoc test
  3. *denotes significant difference compared to control, # denotes significant difference compared to STZ-30, $ denotes significant difference compared to STZ-30-Cap, € denotes significant difference compared to STZ-40, ¥ denotes significant difference compared to STZ-40-Cap, and @ denotes significant difference compared to STZ-50
  4. NO Nitric oxide, GLUT2 Glucose transporter 2, STZ Streptozotocin, Cap Captopril
Back to article page